. Author manuscript; available in PMC: 2014 Oct 3.

Published in final edited form as: Int J Cardiol. 2013 Apr 15;168(3):2567–2574. doi: 10.1016/j.ijcard.2013.03.049

Table 1.

Effect of G-CSF treatment on cardiac MTD in T. cruzi-infected mice.

Infection stage	Morphology	Myocyte transversal diameter (μm)
Infection stage	Morphology	NI	NI + G-CSF	I	I + GCSF
Acute	Unaffected area	11.09 ± 0.86	11.09 ± 0.54	11.08 ± 0.77	11.09 ± 1.03
Acute	Inflamed area	–	–	8.87 ± 0.44^*^†	8.27 ± 0.60^*^†
Chronic	Unaffected area	10.00 ± 0.85	10.33 ± 1.58	11.11 ± 1.38	10.65 ± 1.01
Chronic	Inflamed area	–	–	8.56 ± 0.92^*^†	8.08 ± 0.80^*^†

C3H/He uninfected and T. cruzi infected mice untreated or treated with G-CSF for four weeks, beginning day 21 (acute) or 1 year (chronic) post-infection were subjected to cardiomyocyte measurements by histo-morphometry. Data are presented as mean ± S.D. from analysis of >100 cells at 400× (>10 microscopic fields/slide, 3–4 tissue-sections/mouse, n ≥ 6 mice per group

p < 0.05, vs. normal

^†

p < 0.05 vs. infected/unaffected area). NI: uninfected control, NI + GCSF: uninfected-treated, I: infected, I + GCSF: infected-treated.